SCHEMBL5362837

SCHEMBL5362837

COC(=O)c1cc(Cl)ccc1Oc1cccc(C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 1/20 0.49
PTGER4 P35408 2/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
ABL1 P00519 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
PTGER2 P43116 1/20 0.44
KCNMA1 Q12791 1/20 0.44
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30974620 1.00 L3MBTL1 (0.58) L3MBTL1TDP1PTGER4MRGPRX4ABL1
SCHEMBL4450385 0.90 PTGER4 (0.56) L3MBTL1TDP1PTGER4MRGPRX4ABL1
SCHEMBL30974566 0.89 KDM4E (0.49) L3MBTL1TDP1KDM4EPOLBLMNA
SCHEMBL29250443 0.89 KDM4E (0.49) L3MBTL1TDP1KDM4EPOLBLMNA
SCHEMBL4449372 0.88 KDM4E (0.59) L3MBTL1TDP1PTGER4MRGPRX4ABL1
SCHEMBL5363217 0.86 L3MBTL1 (0.61) L3MBTL1PTGER4MRGPRX4HTR2CHTR2B
SCHEMBL4446808 0.85 PTGER4 (0.59) L3MBTL1TDP1PTGER4MRGPRX4ABL1
SCHEMBL30974584 0.85 L3MBTL1 (0.63) L3MBTL1TDP1PTGER4MRGPRX4HTR2C
SCHEMBL29250434 0.85 L3MBTL1 (0.63) L3MBTL1TDP1PTGER4MRGPRX4HTR2C
SCHEMBL30974583 0.84 PTGER4 (0.48) L3MBTL1TDP1PTGER4MRGPRX4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118084706-A Synthesis method of 2- (4-hydroxyphenoxy) benzamide compound 河北科技大学 2024-05-28 CN disclosed
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
CN-1867551-B Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists RAQUALIA PHARMA INC 2013-09-11 CN disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
CN-1867551-A Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists PFIZER (US) 2006-11-22 CN disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 L3MBTL1 196/4885TDP1 4559/4885PTGER4 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.